Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Seropositive for HCMV IgG antibodies before transplantation~* First allogeneic Human blood precursor cell (HBPC) transplantation performed for 1 of the following diagnoses: leukaemia, lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, myelodysplastic and myeloproliferative disorder~* Evidence of post transplantation engraftment~* Able to swallow tablets.~Exclusion Criteria:~* Previous anti-HCMV therapy after this allogeneic HBPC transplantation~* Mismatched or cord blood transplant recipients~* Current or history of end-organ HCMV disease~* Graft versus host disease (GVHD)~* Impaired liver function~* Reduced renal function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose regimen 1 (Type: EXPERIMENTAL): 60 mg AIC246, one tablet per day
- Dose regimen 2 (Type: EXPERIMENTAL): 120 mg AIC246, one tablet per day
- Dose regimen 3 (Type: EXPERIMENTAL): 240 mg AIC246, one tablet per day
- Placebo (Type: OTHER): Placebo arm

Based on this trial design, predict the completion outcome and termination type (if applicable).